ANALYTICAL METHOD FOR INCREASING SUSCEPTIBILITY OF MOLECULAR TARGETED THERAPY IN HEPATOCELLULAR CARCINOMA

摘要

Provided herein is an analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment by analyzing the mRNA expression of FGFR1, optionally along with the mRNA expressions of other biomarkers (i.e., VEGFR2, PDGFRβ, c-KIT, c-RAF, EGFR, and/or mTOR) to select a patient having susceptibility to sorafenib treatment and a patient having resistance to sorafenib treatment before employing molecular targeted therapy with sorafenib.

主权项

1. An analytical method for determining whether a hepatocellular carcinoma patient has susceptibility or resistance to sorafenib treatment, comprising
(i) measuring mRNA expression levels of the gene of SEQ ID NO: 1 in both hepatocellular carcinoma tissues and normal tissues removed, from the body of the hepatocellular carcinoma patient, and (ii) measuring a ratio between the mRNA expression level of the gene of SEQ ID NO: 1 in the hepatocellular carcinoma tissues and the mRNA expression level of the gene of SEQ ID NO: 1 in the normal tissues.